Get started

BPTH

BPTH - Good News in Dec = Enormous ProfitsBPTH, the ticker to the company Bio Path Holdings is currently trending down. This ticker has been a poor performer for the entire year with small time periods where day traders may make an easy 20-60 percent. Bio Path may seem like a decent day trading target where it follows the downward trending line and tends to bounce up a few days after coming into contact with it. If this continues, one can easily make short term gains and find value in this, but it will make much more sense to wait. Bio Path will be releasing news on its number one drug, Prexigebersen for Acute Myeloid Leukemia (AML). This drug with good data has the potential of making Bio Path a multi billion dollar company. As you can see last year, Bio Path jumped from a startling ~$1 per share to ~$70 per share with one good news release. It is not easy to find these opportunities very often, that's why timing is the key. Bio Medical companies tend to slowly decrease in value or, "bleed" waiting for positive news from the company. This is due to the companies being unprofitable and often seek financing deals creating stock dilution. The good news is what makes the stock relatively value because of the opportunity for day traders to capitalize on large percentage gains with a simple news release, but at the same time, you could also lose a large amount if it were negative. Bio Path will release news on Prexigebersen this December and if you don't know enough about it, I recommend you do a little research on your own. Any investment in this company is indeed speculation. Investing with small positions is the proper strategy with bio-med. Cheers, AC
NASDAQ:BPTHLong
by RayleWoodInvestments
$BPTH Posts Positive Phase 2 Trials for Leukemia DrugBio-Path released updated Phase 2 data for its lead candidate prexigebersen, codenamed BP1001, for treating acute myeloid leukemia, or AML, and also divulged a plan of action for taking the compound through clinical development toward registration. Updated data from the Stage 1 of the Phase 2 study that evaluated the efficacy and safety of prexigebersen in conjunction with the low-dose chemotherapy regimen cytarabine in 17 newly diagnosed AML patients revealed that the proportion of patients showing a response increased from 47 percent when assessed in April 2018 to 65 percent. Of the patients showing a response, 5, or 29 percent, showed a complete response compared to the benchmarked percentage of 7-13 percent. AML: A Cancer Of Blood Cells: AML is a form of blood cancer that develops in the bone marrow, where blood cells originate. It afflicts a group of white blood cells called myeloid cells that develop into mature blood cells such as red blood cells, white blood cells and platelets. A patient with AML will see rapid accumulation of immature myeloid cells in the blood, resulting in a drop of other blood cell types. BP1001's Mode Of Action: Prexigebersen is a neutral-charge, liposome-incorporated antisense drug designed to inhibit protein synthesis of growth factor receptor bound protein 2, or Grb2. Grb2 has a role to play in cancer cell activation via the RAS pathway. Inhibition of Grb2 is found to halt cell proliferation and enhance cell killing by chemotherapeutic agents without added toxicity. A Lucrative Market: AML accounts for roughly 36 percent of all leukemias, with about 20,000 new cases diagnosed each year, Bio-Path said, citing National Cancer Institute estimates. A critically unmet need exists for non-toxic therapies for older, fragile AML patients who are unfit or ineligible for high-dose chemotherapy or a stem cell transplant. What's Next: Bio-Path said it believes it now has a plan with definable paths to registration. It plans to amend the Stage 2 prexigebersen + decitabine Phase 2 AML cohort in untreated new patients to add untreated high-risk myelodysplastic syndrome, or MDS, patients. The company also intends to cancel the Stage 2 prexigebersen + LDAC Phase 2 AML cohort in untreated de novo patients. It also plans to test a triple combo of prexigebersen + decitabine + venetoclax for untreated AML and high-risk MDS patients in a registration-directed trial to determine if more durable responses and longer survival are observed compared to patients treated with the decitabine + venetoclax combination. The next major catalyst for Bio-Path will be the fourth-quarter results expected sometime in the next month.
NASDAQ:BPTHLong
by StockGuild